CLNN - Clene Inc

-

$undefined

N/A

(N/A)

Clene Inc NasdaqCM:CLNN Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Location: 6550 South Millrock Drive, Salt Lake City, UT, 84121, United States | Website: https://clene.com | Industry: Packaged Foods | Sector: Consumer Defensive


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

35.72M

Cash

9.832M

Avg Qtr Burn

-4.814M

Short % of Float

2.77%

Insider Ownership

34.63%

Institutional Own.

16.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CNM-Au8 Details
Amyotrophic lateral sclerosis

NDA

Submission

CNM-Au8 Details
Multiple sclerosis

Phase 2

Data readout

CNM-Au8 Details
Amyotrophic lateral sclerosis

Phase 2

Update

CNM-Au8 Details
Multiple sclerosis

Phase 2

Update

CNM-Au8 Details
Parkinson's disease

Failed

Discontinued

Failed

Discontinued